Native Polistes wasps (Hymenoptera: Vespidae) hold potential as biocontrol agents for lepidopteran pests of Brassica.

Social paper wasps regularly prey upon lepidopteran larvae, some of which are economically impactful agricultural pest species. We examined the potential of native North American Polistes metricus Say (Hymenoptera: Vespidae) and Polistes fuscatus (Fabricius) for biocontrol of Brassica L. pests in an experimental setting. First, we translocated P. metricus to one-half of a divided screened hoop house and placed a mix of 4th-5th instar lepidopteran larvae (Trichoplusia ni (Hübner) (Lepidoptera: Noctuidae), Pieris spp. Schrank (Lepidoptera: Pieridae), and Plutella xylostella (L.) (Lepidoptera: Plutellidae)) on half of the broccoli plants on both sides of the hoop house. We recorded and replaced missing caterpillars daily, and assessed leaf damage after 1 wk. P. metricus was 100% effective at removing all caterpillars from the wasp side of the hoop house, and plant damage by caterpillars was significantly reduced in the presence of wasps. We then replicated the study using a different combination of Polistes (fuscatus) and Brassica crop (kale) with a 2 × 2 experimental design in which plants had either T. ni larvae added or absent (factor 1), and were either covered with insect mesh or left exposed (factor 2). By the second day of exposure to these pest species, wasps removed over 80% of the larvae within 3 h of placing them on the plants. We discuss implications of this study for the potential use of native Polistes wasps as an integrated pest management strategy.

Analysis of US Food and Drug Administration Warning Letters: False Promotional Claims Relating to Prescription and Over-the-Counter Medications.

BACKGROUND: Recent studies have suggested that there has been an increase in the number of 'warning letters' issued by the US Food and Drug Administration (FDA) despite the publication of the FDA advertising guidelines. However, limited information is available on the description of warning letters. The objective of this study was to analyse the frequency and content of FDA warning letters in relation to promotional claims and discuss the influence of regulatory and industry constraints on promotion. METHODS: All warning letters published by the FDA between 5 May 1995 and 11 June 2007 were reviewed. Warning letters related to promotional issues were included and analysed. Information related to the identification number, date of the warning letter, FDA division that issued the letter, drug name, manufacturer, specific warning problem, type of promotional material and requested action was extracted. Two independent investigators reviewed and classified each PDF file, any differences were discussed until a consensus was reached. RESULTS: Between May 1995 and June 2007 a total of 8692 warning letters were issued, of which 25% were related to drugs. Of these, 206 warning letters focused on drug promotion and were included in this study: 23% were issued in 2005, 15% in 2004 and 14% in 1998. In total, 47% of the warning letters were issued because of false or misleading unapproved doses and uses, 27% failed to disclose risks, 15% cited misleading promotion, 8% related to misleading labelling and 3% promoted false effectiveness claims. DISCUSSION: There is an important variation in the number of warning letters issued in the last decade, probably because of the increasing number of drugs approved by the FDA, drug withdrawal scandals, and the publication of the FDA and the Pharmaceutical Research and Manufacturers of America (PhRMA) guidelines. CONCLUSION: We found that benefit-related claims, such as unapproved uses or doses of drugs, and failure to disclose risks, are the main causes of FDA issued warning letters for promotional claims related to medications.

Maternal hair dye use and risk of neuroblastoma in offspring.

OBJECTIVE: Studies have suggested an association between maternal hair dye use and elevated risk of childhood cancer, including neuroblastoma. We analyzed data from a large case-control study to investigate the relationship between maternal hair dye use around pregnancy and risk of neuroblastoma in offspring. METHODS: Cases were children with neuroblastoma diagnosed between 1992 and 1994 at hospitals in the United States and Canada participating in the Children's Cancer Group or the Pediatric Oncology Group. Random-digit dialing was used to identify one matched control for each case. Information on hair dye use was gathered from telephone interviews of 538 case and 504 control mothers. RESULTS: Use of any hair dye in the month before and/or during pregnancy was associated with a moderately increased risk of neuroblastoma (adjusted odds ratio (OR) = 1.6; 95% confidence interval (CI) = 1.2-2.2). Temporary hair dye use (OR = 2.0, CI = 1.1-3.7) was more strongly associated with neuroblastoma than use of permanent hair dye (OR = 1.4, CI = 1.0-2.0). CONCLUSION: Although the results of this study provide evidence of an association between maternal hair dye use and neuroblastoma, further research is necessary to evaluate effects by method of hair dye application, color, and chemical composition.